Anti-CD22 therapeutic antibodies have been developed in different forms, and an antibody called epratuzumab has been clinically studied in B cell malignancies, such as non-Hodgkin’s lymphoma and systemic lupus erythematosus (50). This evidence concerns the gene CD22 and non-Hodgkin lymphoma.